Treatment of Benign Prostatic Hyperplasia with Acute Urinary Retention
Clinical Scenario
This protocol is for patients who develop acute urinary retention (AUR) related to benign prostatic hyperplasia — an urgent presentation where bladder drainage alone is not sufficient and specific medical therapy is required before catheter removal can be attempted.
Management Approach
An oral alpha blocker is prescribed prior to a voiding trial. The protocol defines which agents qualify, the minimum duration of therapy required, and the conditions under which a trial without catheter (TWOC) should be attempted — the complete regimen is available below.
Clinical Goals
- Successful voiding after trial without catheter (TWOC)
- Resolution of urinary retention
References
- Physicians should prescribe an oral alpha blocker prior to a voiding trial to treat patients with AUR related to BPH.
- Patients newly treated for AUR with alpha blockers should complete at least three days of medical therapy prior to attempting trial without a catheter (TWOC).
DOI: 10.1097/JU.0000000000003698
View source ↗